Skip to main content
. 2019 Jul 31;11(8):1084. doi: 10.3390/cancers11081084

Figure 3.

Figure 3

Progression free survival (PFS) in both groups with Child–Pugh A liver function after propensity score matching. PFS in the lenvatinib-treated group was significantly better than that in the TACE-treated group (16.0 months vs. 3.0 months; hazard ratio (HR) 0.19, p < 0.001).